| OLMA |
Olema Pharmaceuticals, Inc. |
Common Stock, $0.0001 par value per share |
10% |
$37,443,949 |
|
7,429,355 |
|
Paradigm BioCapital Advisors LP |
31 Dec 2024 |
| ACLX |
Arcellx, Inc. |
Common Stock, $0.001 par value per share |
9.9% |
$379,330,540 |
|
5,724,016 |
|
Paradigm BioCapital Advisors LP |
31 Dec 2025 |
| URGN |
UroGen Pharma Ltd. |
Ordinary Shares, par value NIS 0.01 per share |
9% |
$84,110,876 |
+$37,586,159 |
4,216,084 |
+81% |
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| LXEO |
Lexeo Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
6.5% |
$35,390,561 |
+$8,107,609 |
4,763,198 |
+30% |
Paradigm BioCapital Advisors LP |
31 Dec 2025 |
| EWTX |
Edgewise Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
6.2% |
$161,371,651 |
+$44,462,272 |
6,541,210 |
+38% |
Paradigm BioCapital Advisors LP |
31 Dec 2025 |
| ERAS |
Erasca, Inc. |
Common Stock, $0.0001 par value per share |
5.3% |
$56,391,833 |
|
15,159,095 |
|
Paradigm BioCapital Advisors LP |
07 Jan 2026 |
| EYPT |
EyePoint, Inc. |
Common Stock, $0.001 par value per share |
5.1% |
$64,770,432 |
|
4,192,261 |
|
Paradigm BioCapital Advisors LP |
17 Feb 2026 |
| AGIO |
Agios Pharmaceuticals, Inc. |
Common Stock, $0.001 par value per share |
4.9% |
$115,344,498 |
-$6,198,499 |
2,873,555 |
-5.1% |
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| JANX |
Janux Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
4.9% |
$73,444,489 |
-$14,982,559 |
2,920,258 |
-17% |
Paradigm BioCapital Advisors LP |
30 Jun 2025 |
| VOR |
VOR Biopharma Inc. |
Common Stock, $0.0001 par value per share |
4.5% |
$23,730,000 |
|
1,750,000 |
0% |
Paradigm BioCapital Advisors LP |
31 Dec 2025 |
| LENZ |
LENZ Therapeutics, Inc. |
Common Stock, $0.00001 par value per share |
3.8% |
$50,001,813 |
-$16,133,961 |
1,073,461 |
-24% |
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| IRON |
Disc Medicine, Inc. |
Common Stock, $0.0001 par value per share |
3.5% |
$57,097,283 |
|
1,210,971 |
|
Paradigm BioCapital Advisors LP |
31 Mar 2025 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
3.3% |
$92,041,065 |
-$16,034,916 |
961,164 |
-15% |
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| COGT |
Cogent Biosciences, Inc. |
Common Stock, $0.001 par value per share |
2.3% |
$45,325,875 |
-$103,335,292 |
3,156,398 |
-70% |
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| PLRX |
Pliant Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
|
0 |
|
Paradigm BioCapital Advisors LP |
31 Mar 2025 |
| KURA |
Kura Oncology, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
|
0 |
|
Paradigm BioCapital Advisors LP |
31 Dec 2024 |
| YMAB |
Y-mAbs Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
|
0 |
|
Paradigm BioCapital Advisors LP |
30 Sep 2025 |
| MRUS |
Merus N.V. |
Common Shares, (euro)0.09 nominal value per share |
0% |
$0 |
-$420,639,300 |
0 |
-100% |
Paradigm BioCapital Advisors LP |
31 Dec 2025 |